The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2025

Filed:

Mar. 23, 2020
Applicants:

University of Ulsan Foundation for Industry Cooperation, Ulsan, KR;

The Asan Foundation, Seoul, KR;

Inventors:

Kyung Jin Lee, Hanam-si, KR;

Sin Hwang, Seoul, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/574 (2006.01); C07K 16/18 (2006.01); C12N 5/16 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
G01N 33/57438 (2013.01); C07K 16/18 (2013.01); C12N 5/163 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/471 (2013.01); G01N 2800/52 (2013.01);
Abstract

Provided are the use of cereblon (CRBN) as a biomarker for diagnosis of hepatocellular carcinoma and novel monoclonal antibodies specific to CRBN. More specifically, provided are a composition and a kit for diagnosing or predicting the prognosis of hepatocellular carcinoma by using CRBN as a biomarker for diagnosis of hepatocellular carcinoma, an information providing method for diagnosing or predicting the prognosis of hepatocellular carcinoma, two novel monoclonal antibodies binding specifically to CRBN, and hybridoma cells producing the same. The expression level difference of CRBN protein allows patients with hepatocellular carcinoma to be diagnosed early and indicates better predictive capabilities than the presence or absence of microvascular invasion, which was an important factor in predicting a prognosis of hepatocellular carcinoma in prior art, and thus can be expected to be used as a diagnostic marker to diagnose hepatocellular carcinoma and to evaluate a prognosis after hepatic resection.


Find Patent Forward Citations

Loading…